St. John's Wort for Menopause

Verdict: Promising but unproven for menopause symptoms

St. John's Wort may modestly ease menopausal hot flashes and related mood symptoms, but the evidence comes from small, mixed trials and major medical bodies do not recommend it. It is also a potent drug-interaction risk, so it should not be self-prescribed alongside hormones, contraceptives, anticoagulants, or antidepressants.

B 🟡 B Preliminary Evidence Disputed

🔬Why this grade7-layer evidence engine

The grade is Preliminary (Tier B), Disputed, because the human trial data lean positive but are thin and inconsistent. A 2014 meta-analysis (PMID 24188229) found Hypericum preparations clearly better than placebo for menopausal symptoms (SMD -1.08, 95% CI -1.38 to -0.77), and individual RCTs of St. John's Wort alone (PMID 20216274; PMID 31331546) plus a systematic review (PMID 27462550) reported fewer and milder hot flashes.

What keeps this out of a higher tier is the quality of that evidence. The trials are small, single-center studies (n=80-301), some test combination products that cannot isolate St. John's Wort itself, and the largest positive trial (PMID 16449108, St. John's Wort plus black cohosh, n=301) was industry-funded. Crucially, a St. John's Wort plus Vitex trial (PMID 18791483) showed no benefit over placebo, so results are genuinely heterogeneous.

Authoritative reviewers are split or cautious, which drives the Disputed status. Mayo Clinic calls the menopause evidence preliminary ('some research ... might lessen' hot flashes), while The Menopause Society advises against OTC botanicals for vasomotor symptoms. Regulators (FDA, WHO) only recognize St. John's Wort for mild-to-moderate depression, not menopause, and flag it as a strong CYP3A4/P-glycoprotein inducer that can dangerously cut the effectiveness of contraceptives, anticoagulants, and many other drugs.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.56
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Disputed
Confidence
64%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.35
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.65
L11 AI re-checkIndependent read
0.65
L2 PubMedPrimary literature
0.75
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.56
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 1 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (6)L2 · primary research & systematic reviews

Hypericum perforatum L. preparations for menopause: a meta-analysis of efficacy and safety
PMID: 24188229 2014 統合分析
Finding: Pooled analysis found Hypericum perforatum preparations significantly superior to placebo for menopausal symptoms (SMD -1.08, 95% CI -1.38 to -0.77); adverse events were not significantly different from placebo (17.4% vs 15.4%, RR 1.16, 95% CI 0.81-1.66), and the authors concluded SJW preparations are effective with a favourable safety profile.
Effect size: [object Object]
View on PubMed
Effects of flaxseed and Hypericum perforatum on hot flash, vaginal atrophy and estrogen-dependent cancers in menopausal women: a systematic review and meta-analysis
PMID: 27462550 2016 系統性回顧
Finding: This systematic review of nine RCTs reported that Hypericum perforatum reduces hot flash frequency and intensity in menopausal women, with one trial showing Vitex agnus-castus and H. perforatum producing a comparable decrease in hot flash frequency; no pooled SMD or CI specific to H. perforatum was reported in the abstract.
View on PubMed
Black cohosh and St. John's wort for climacteric complaints: a randomized trial
PMID: 16449108 2006 RCT (double-blind) n = 301
Finding: In 301 women with climacteric complaints plus psychological symptoms, the SJW+black cohosh combination cut the Menopause Rating Scale score by 50% vs 19.6% for placebo and the Hamilton Depression score by 41.8% vs 12.7% (P < .001), being significantly superior to placebo with adverse events comparable to placebo.
⚠️ Industry-funded Effect size: [object Object]
View on PubMed
The effect of Hypericum perforatum on postmenopausal symptoms and depression: A randomized controlled trial
PMID: 31331546 2019 RCT (double-blind) n = 80
Finding: In 80 postmenopausal women aged 45-60 (Iran), SJW significantly reduced hot flash frequency/intensity and Kupperman index versus placebo (p < 0.001), and reduced depression severity such that 80% of the SJW group had no depression at week 8 vs 5.7% of controls (p < 0.001).
View on PubMed
Effect of St John's wort on severity, frequency, and duration of hot flashes in pre-/peri-/postmenopausal women: an RCT
PMID: 20216274 2010 RCT (double-blind) n = 100
Finding: In 100 pre-, peri- and postmenopausal women, both groups improved within-group, but SJW was significantly superior to placebo between groups for hot flash frequency (P = 0.005 at wk 4, P < 0.001 at wk 8), severity (P = 0.004 and P < 0.001) and duration (P < 0.001 by wk 8); authors concluded SJW is an effective treatment for vasomotor symptoms.
View on PubMed
Hypericum perforatum with Vitex agnus-castus in menopausal symptoms: a randomized, controlled trial
PMID: 18791483 2009 RCT (double-blind) n = 100
Finding: In 100 randomized women (93 completers) the SJW+Vitex combination showed no significant difference versus placebo on any endpoint including hot flushes; significant within-group improvement occurred in both arms, indicating no benefit over placebo for this herbal combination.
Academic
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
St. John's Wort appears to be an inducer of an important metabolic pathway, cytochrome P450. As many prescription drugs used to treat conditions such as heart disease, depression, seizures, certain cancers or to prevent conditions such as transplant rejection or pregnancy (oral contraceptives) are metabolized via this pathway, health care providers should alert patients about these potential dr… source↗
L4b EU EFSA
Cautious
L4c UK NHS
Against
St John's wort is a herbal treatment that some people take for depression. ... There's some evidence that it may help less severe depression, but it's not recommended by doctors. This is because the amount of active ingredients varies among individual brands and batches, so you can never be sure what sort of effect it'll have on you. Taking St John's wort with other medicines, such as anticonvu… source↗
L4d TW TFDA / 衛福部
Cautious
根據台灣衛生福利部的規定,聖約翰草不能當作一般食品原料使用,因此在台灣無法購買到合法含有聖約翰草的食品。 source↗
L4e WHO
Supportive
Herba Hyperici. WHO Monographs on Selected Medicinal Plants, Volume 2 (Geneva: World Health Organization, 2002), pp. 149-171. The crude drug herba hyperici consists of the dried flowering aerial parts of Hypericum perforatum L. Uses supported by clinical data include the symptomatic treatment of mild to moderate depressive disorders. Verbatim section text of the WHO monograph could not be extra… source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Cautious
Some research suggests that taking St. John's wort alone or with black cohosh or other herbs might lessen menopause symptoms such as hot flashes. source↗
L5c Cleveland Clinic
Cautious
L5d Harvard Health
Neutral
L5e Specialty Society (condition-mapped)
Against
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬6 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-menopause-INT-st-johns-wort-001 繁體中文版 →